Trifonova Oxana P, Maslov Dmitri L, Balashova Elena E, Urazgildeeva Guzel R, Abaimov Denis A, Fedotova Ekaterina Yu, Poleschuk Vsevolod V, Illarioshkin Sergey N, Lokhov Petr G
Laboratory of mass spectrometry-based metabolomics diagnostics, Institute of Biomedical Chemistry, 10 building 8, Pogodinskaya street, 119121 Moscow, Russia.
5th Neurological Department (Department of Neurogenetics), Research Centre of Neurology, Volokolamskoe shosse, 80, 125367 Moscow, Russia.
Diagnostics (Basel). 2020 May 25;10(5):339. doi: 10.3390/diagnostics10050339.
Parkinson's disease is the second most frequent neurodegenerative disease, representing a significant medical and socio-economic problem. Modern medicine still has no answer to the question of why Parkinson's disease develops and whether it is possible to develop an effective system of prevention. Therefore, active work is currently underway to find ways to assess the risks of the disease, as well as a means to extend the life of patients and improve its quality. Modern studies aim to create a method of assessing the risk of occurrence of Parkinson's disease (PD), to search for the specific ways of correction of biochemical disorders occurring in the prodromal stage of Parkinson's disease, and to personalize approaches to antiparkinsonian pharmacotherapy. In this review, we summarized all available clinically approved tests and techniques for PD diagnostics. Then, we reviewed major improvements and recent advancements in genomics, transcriptomics, and proteomics studies and application of metabolomics in PD research, and discussed the major metabolomics findings for diagnostics and therapy of the disease.
帕金森病是第二常见的神经退行性疾病，是一个重大的医学和社会经济问题。现代医学仍无法回答帕金森病为何会发病以及是否有可能建立有效的预防体系这一问题。因此，目前正在积极开展工作，以寻找评估该疾病风险的方法，以及延长患者寿命并提高其生活质量的手段。现代研究旨在创建一种评估帕金森病（PD）发病风险的方法，寻找纠正帕金森病前驱期发生的生化紊乱的具体方法，并使抗帕金森药物治疗方法个性化。在本综述中，我们总结了所有现有的经临床批准的PD诊断测试和技术。然后，我们回顾了基因组学、转录组学和蛋白质组学研究的主要进展以及代谢组学在PD研究中的应用，并讨论了该疾病诊断和治疗的主要代谢组学发现。
